

Daniel E Johnson

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8380675/daniel-e-johnson-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58

papers

5,799

citations

22

h-index

63

g-index

63

ext. papers

7,308

ext. citations

8.2

avg, IF

6.05

L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 58 | Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012 , 8, 445-544 | 14.2 | 2783 |
| 57 | Targeting the IL-6/JAK/STAT3 signalling axis in cancer. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 234-248 | 18.4 | 975 |
| 56 | Head and neck squamous cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 92 | 51.1 | 397 |
| 55 | Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 4138-43 | 11.5 | 284 |
| 54 | First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. <i>Cancer Discovery</i> , 2012 , 2, 694-705 | 24.4 | 214 |
| 53 | Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 4986-96 | 12.9 | 120 |
| 52 | EGFR-targeted therapies in the post-genomic era. <i>Cancer and Metastasis Reviews</i> , 2017 , 36, 463-473 | 9.6 | 95 |
| 51 | The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. <i>Endocrine-Related Cancer</i> , 2015 , 22, T1-17 | 5.7 | 70 |
| 50 | Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. <i>Molecular Pharmacology</i> , 2007 , 71, 1435-43 | 4.3 | 63 |
| 49 | Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 1114-9 | 11.5 | 62 |
| 48 | Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. <i>Cancer Prevention Research</i> , 2016 , 9, 547-57 | 3.2 | 56 |
| 47 | Fas stimulation induces RB dephosphorylation and proteolysis that is blocked by inhibitors of the ICE protease family. <i>Journal of Cellular Biochemistry</i> , 1997 , 64, 586-594 | 4.7 | 47 |
| 46 | Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2211-20 | 6.1 | 45 |
| 45 | Lack of toxicity of a STAT3 decoy oligonucleotide. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 983-95 | 3.5 | 44 |
| 44 | Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. <i>Molecular Oncology</i> , 2014 , 8, 1220-30 | 7.9 | 42 |
| 43 | Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for -altered head and neck cancer. <i>Journal of Experimental Medicine</i> , 2019 , 216, 419-427 | 16.6 | 34 |
| 42 | New Therapies in Head and Neck Cancer. <i>Trends in Cancer</i> , 2018 , 4, 385-396 | 12.5 | 34 |

| | | | |
|----|--|------|----|
| 41 | Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV Patients. <i>Clinical Cancer Research</i> , 2017 , 23, 3072-3083 | 12.9 | 33 |
| 40 | An ATRActive future for differentiation therapy in AML. <i>Blood Reviews</i> , 2015 , 29, 263-8 | 11.1 | 31 |
| 39 | Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. <i>Molecular Medicine</i> , 2014 , 20, 46-56 | 6.2 | 30 |
| 38 | STAT transcription factors in normal and cancer stem cells. <i>Advances in Biological Regulation</i> , 2014 , 56, 30-44 | 6.2 | 27 |
| 37 | Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis. <i>Advances in Enzyme Regulation</i> , 2008 , 48, 98-112 | | 24 |
| 36 | An update: emerging drugs to treat squamous cell carcinomas of the head and neck. <i>Expert Opinion on Emerging Drugs</i> , 2018 , 23, 283-299 | 3.7 | 21 |
| 35 | Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. <i>Cancer Research</i> , 2018 , 78, 2383-2395 | 10.1 | 20 |
| 34 | Targeting STAT3 in Cancer with Nucleotide Therapeutics. <i>Cancers</i> , 2019 , 11, | 6.6 | 20 |
| 33 | Chemoprevention targets for tobacco-related head and neck cancer: past lessons and future directions. <i>Oral Oncology</i> , 2015 , 51, 557-64 | 4.4 | 19 |
| 32 | STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 1917-1926 | 6.1 | 19 |
| 31 | Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells. <i>Oral Oncology</i> , 2014 , 50, 120-7 | 4.4 | 18 |
| 30 | Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. <i>Cancer Biology and Therapy</i> , 2014 , 15, 1142-52 | 4.6 | 17 |
| 29 | Targeting the JAK/STAT pathway in solid tumors. <i>Journal of Cancer Metastasis and Treatment</i> , 2020 , 6, | 3.8 | 17 |
| 28 | ATR inhibition sensitizes HPV and HPV head and neck squamous cell carcinoma to cisplatin. <i>Oral Oncology</i> , 2019 , 95, 35-42 | 4.4 | 15 |
| 27 | NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer. <i>Advances in Biological Regulation</i> , 2020 , 75, 100653 | 6.2 | 14 |
| 26 | Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. <i>Seminars in Radiation Oncology</i> , 2018 , 28, 2-11 | 5.5 | 12 |
| 25 | Signaling by cell surface death receptors: Alterations in head and neck cancer. <i>Advances in Biological Regulation</i> , 2018 , 67, 170-178 | 6.2 | 12 |
| 24 | Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit. <i>Chinese Journal of Cancer</i> , 2012 , 31, 319-26 | | 11 |

| | | | |
|----|---|------|---|
| 23 | Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 351-363 | 5.9 | 9 |
| 22 | Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020 , 1867, 118679 | 4.9 | 7 |
| 21 | A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2595-2601 | 1.9 | 7 |
| 20 | Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor. <i>International Journal of Molecular Sciences</i> , 2018 , 19, | 6.3 | 7 |
| 19 | Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that Loss Contributes to Cetuximab Resistance in Head and Neck Cancer. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1562-1571 | 6.1 | 6 |
| 18 | A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. <i>Science</i> , 2021 , 374, eabf2911 | 33.3 | 6 |
| 17 | STAT3 decoy oligonucleotide-carrying microbubbles with pulsed ultrasound for enhanced therapeutic effect in head and neck tumors. <i>PLoS ONE</i> , 2020 , 15, e0242264 | 3.7 | 5 |
| 16 | Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. <i>PLoS ONE</i> , 2020 , 15, e0227261 | 3.7 | 4 |
| 15 | Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 219-228 | 6.1 | 4 |
| 14 | CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers. <i>Molecular Cancer Research</i> , 2021 , 19, 14-24 | 6.6 | 4 |
| 13 | Characterization of caspase proteases in cytokine-dependent myeloid progenitor cells using enzyme affinity labeling. <i>Journal of Cellular Biochemistry</i> , 1999 , 73, 79-89 | 4.7 | 3 |
| 12 | Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. <i>PLoS ONE</i> , 2016 , 11, e0166185 | 3.7 | 3 |
| 11 | Gene targets of sulforaphane in head and neck squamous cell carcinoma. <i>Molecular Medicine Reports</i> , 2019 , 20, 5335-5344 | 2.9 | 2 |
| 10 | PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance. <i>Head and Neck</i> , 2021 , 43, 3364-3373 | 4.2 | 2 |
| 9 | NSAIDs Overcome Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models.. <i>Cancers</i> , 2022 , 14, | 6.6 | 1 |
| 8 | Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 3739-3739 ^{2.2} | | 1 |
| 7 | Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction. <i>Cell Death and Disease</i> , 2021 , 12, 775 | 9.8 | 1 |
| 6 | The Herbicide Isoproturon Induces Activation-Induced Cytidine Deaminase Expression in Germinal Center B Cells. <i>Blood</i> , 2015 , 126, 4816-4816 | 2.2 | |

- 5 A sensible approach to targeting STAT3-mediated transcription. *Annals of Translational Medicine*, **2016**, 4, S57 3.2
- 4 Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance **2020**, 15, e0227261
- 3 Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance **2020**, 15, e0227261
- 2 Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance **2020**, 15, e0227261
- 1 Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance **2020**, 15, e0227261